MetaVia Inc (MTVA)
MetaVia Inc. is a clinical-stage biotechnology company focused on developing pharmaceutical candidates for cardiometabolic diseases. Its pipeline includes DA-1241, a G-protein-coupled receptor 119 agonist being studied as a standalone and potential combination therapy, and DA-1726, an oxyntomodulin analogue designed as a dual GLP-1 receptor and glucagon receptor agonist. DA-1241 is in Phase 2a testing for metabolic dysfunction-associated steatohepatitis and previously completed a Phase 1 study in type 2 diabetes, while DA-1726 is in Phase 1 development for obesity. The company also advances ANA001 for moderate COVID-19, NB-01 for painful diabetic neuropathy, NB-02 for cognitive impairment, and Gemcabene for dyslipidemia. MetaVia is headquartered in Cambridge, Massachusetts, has a license agreement with Pfizer for Gemcabene, and relies on Dong-A ST as the sole manufacturer for DA-1241 and DA-1726. Formerly known as NeuroBo Pharmaceuticals, the company adopted the MetaVia name in November 2024 and operates as a subsidiary of Dong-A ST Co., Ltd.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-MTVA
|
$1.94
|
15.4% Upside
|
Fair
|
$19.33 1,050.8% Upside
|
Not available
|
Bargain
|
Fair
|
0.0%
|
November 16, 2026
|
1.6x
|
11.068 M
|
-1.457 M
|
1.6%
|
72.8%
|
-38.7
|
109.6%
|
